Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism.
Cinnarizine and flunarizine are piperazine derivatives with calcium antagonist and anticonvulsant properties and are used widely in the treatment of vertigo and circulatory disorders. They have been implicated recently in the aggravation, or even the induction, of parkinsonism in elderly patients. Because the aetiology of parkinsonism has been suggested as having a mitochondrial component, we have investigated the effects of both compounds on mitochondrial respiration and on the activities of the individual respiratory chain complexes. In intact mitochondria from rat liver, both drugs inhibited respiration rates, with substrates entering at Complex I (glutamate/malate) and Complex II (succinate). These effects could be explained by potent inhibitions (Ki 3-10 microM) of both complexes. Complex I is inhibited at a site near the ubiquinone-binding site, which is not competitive with respect to ubiquinone, whereas the inhibition of Complex II is apparently caused by competition with ubiquinone. Furthermore, the inhibition of NADH oxidation by flunarizine in submitochondrial particles caused an NADH-dependent generation of superoxide. These inhibitory properties of both compounds could be significant factors in the aggravation or induction of parkinsonism in elderly patients, in whom mitochondrial function already may be impaired.
Veitch
K
K
Hormone and Metabolic Research Unit, University of Louvain Medical School, Brussels, Belgium.
Hue
L
L
D000818:Animals; D002936:Cinnarizine / Q000494:pharmacology*; D004579:Electron Transport / Q000187:drug effects; D042963:Electron Transport Complex II; D005444:Flunarizine / Q000494:pharmacology*; D008929:Mitochondria, Heart / Q000187:drug effects* / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000378:metabolism; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000037:antagonists & inhibitors*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000201:enzymology; D051381:Rats; D013367:Submitochondrial Particles; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors*
D009097:Multienzyme Complexes; D002936:Cinnarizine; D010088:Oxidoreductases; D042963:Electron Transport Complex II; D013385:Succinate Dehydrogenase; D016660:NAD(P)H Dehydrogenase (Quinone); D005444:Flunarizine